Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus CUPRIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM DISODIUM VERSENATE versus CUPRIMINE.
CALCIUM DISODIUM VERSENATE vs CUPRIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
None Documented
None Documented
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Category C
Category C
Chelating Agent
Chelating Agent